These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 33153414)

  • 21. Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.
    Loong HH; Kwan SS; Mok TS; Lau YM
    Curr Treat Options Oncol; 2018 Sep; 19(11):58. PubMed ID: 30267319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
    Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.
    Hou B; Lu X; Gao DC; Liu QX; Zhou D; Zheng H; Dai JG
    Pak J Pharm Sci; 2021 Jul; 34(4):1459-1468. PubMed ID: 34799322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
    Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
    Lau SC; Chooback N; Ho C; Melosky B
    Clin Lung Cancer; 2019 Sep; 20(5):e576-e583. PubMed ID: 31178389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
    Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
    Chang HC; Huang KT; Tseng CC; Chen YM; Lai CH; Chang YP; Chen YC; Chuang HY; Wang CC
    Thorac Cancer; 2023 Nov; 14(32):3217-3225. PubMed ID: 37704454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
    Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Girard N
    Future Oncol; 2018 May; 14(11):1117-1132. PubMed ID: 29336166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
    Yamamoto N; Mera T; Märten A; Hochmair MJ
    Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
    Schuler M; Fischer JR; Grohé C; Gütz S; Thomas M; Kimmich M; Schneider CP; Laack E; Märten A;
    Oncologist; 2014 Oct; 19(10):1100-9. PubMed ID: 25232040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
    Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
    Masood A; Kancha RK; Subramanian J
    Semin Oncol; 2019 Jun; 46(3):271-283. PubMed ID: 31558282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.